Table of Contents Author Guidelines Submit a Manuscript
Dermatology Research and Practice
Volume 2015 (2015), Article ID 409637, 11 pages
http://dx.doi.org/10.1155/2015/409637
Review Article

Exploring the Physiological Link between Psoriasis and Mood Disorders

1Department of Family Medicine, Broadlawns Medical Center, Des Moines, IA 50314, USA
2Carver College of Medicine, University of Iowa, Iowa City, IA 52242, USA
3Department of Dermatology, University of Iowa, Iowa City, IA 52242, USA
4Department of Pathology, University of Iowa, Iowa City, IA 52242, USA
5Department of Psychiatry, University of Iowa, Iowa City, IA 52242, USA
6Department of Internal Medicine, University of Iowa, Iowa City, IA 52242, USA
7Department of Epidemiology, College of Public Health, University of Iowa, Iowa City, IA 52242, USA

Received 29 May 2015; Accepted 27 September 2015

Academic Editor: Desmond Tobin

Copyright © 2015 Cody J. Connor et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. F. O. Nestle, D. H. Kaplan, and J. Barker, “Psoriasis,” The New England Journal of Medicine, vol. 361, no. 5, pp. 496–509, 2009. View at Publisher · View at Google Scholar · View at Scopus
  2. S. R. Rapp, S. R. Feldman, M. L. Exum, A. B. Fleischer, and D. M. Reboussin, “Psoriasis causes as much disability as other major medical diseases,” Journal of the American Academy of Dermatology, vol. 41, no. 3, part 1, pp. 401–407, 1999. View at Publisher · View at Google Scholar · View at Scopus
  3. M. A. Gupta and A. K. Gupta, “Psychiatric and psychological co-morbidity in patients with dermatologic disorders: epidemiology and management,” American Journal of Clinical Dermatology, vol. 4, no. 12, pp. 833–842, 2003. View at Publisher · View at Google Scholar · View at Scopus
  4. S. K. Kurd, A. B. Troxel, P. Crits-Christoph, and J. M. Gelfand, “The risk of depression, anxiety, and suicidality in patients with psoriasis: a population-based cohort study,” Archives of Dermatology, vol. 146, no. 8, pp. 891–895, 2010. View at Publisher · View at Google Scholar · View at Scopus
  5. M. Ghajarzadeh, M. Ghiasi, and S. Kheirkhah, “Associations between skin diseases and quality of life: a comparison of psoriasis, vitiligo, and alopecia areata,” Acta Medica Iranica, vol. 50, no. 7, pp. 511–515, 2012. View at Google Scholar · View at Scopus
  6. M. Karelson, H. Silm, and K. Kingo, “Quality of life and emotional state in vitiligo in an Estonian sample: comparison with psoriasis and healthy controls,” Acta Dermato Venereologica, vol. 93, no. 4, pp. 446–450, 2013. View at Publisher · View at Google Scholar · View at Scopus
  7. V. Kumar, S. K. Mattoo, and S. Handa, “Psychiatric morbidity in pemphigus and psoriasis: a comparative study from India,” Asian Journal of Psychiatry, vol. 6, no. 2, pp. 151–156, 2013. View at Publisher · View at Google Scholar · View at Scopus
  8. N. Sharma, R. V. Koranne, and R. K. Singh, “Psychiatric morbidity in psoriasis and vitiligo: a comparative study,” Journal of Dermatology, vol. 28, no. 8, pp. 419–423, 2001. View at Publisher · View at Google Scholar · View at Scopus
  9. A. Mufaddel and A. E. Abdelgani, “Psychiatric comorbidity in patients with psoriasis, vitiligo, acne, eczema and group of patients with miscellaneous dermatological diagnoses,” Open Journal of Psychiatry, vol. 4, no. 3, pp. 168–175, 2014. View at Publisher · View at Google Scholar
  10. J. D. Rosenblat, D. S. Cha, R. B. Mansur, and R. S. McIntyre, “Inflamed moods: a review of the interactions between inflammation and mood disorders,” Progress in Neuro-Psychopharmacology and Biological Psychiatry, vol. 53, pp. 23–34, 2014. View at Publisher · View at Google Scholar · View at Scopus
  11. Y. Dowlati, N. Herrmann, W. Swardfager et al., “A meta-analysis of cytokines in major depression,” Biological Psychiatry, vol. 67, no. 5, pp. 446–457, 2010. View at Publisher · View at Google Scholar · View at Scopus
  12. C. Pizzi, S. Mancini, L. Angeloni, F. Fontana, L. Manzoli, and G. M. Costa, “Effects of selective serotonin reuptake inhibitor therapy on endothelial function and inflammatory markers in patients with coronary heart disease,” Clinical Pharmacology and Therapeutics, vol. 86, no. 5, pp. 527–532, 2009. View at Publisher · View at Google Scholar · View at Scopus
  13. A. Steptoe, M. Hamer, and Y. Chida, “The effects of acute psychological stress on circulating inflammatory factors in humans: a review and meta-analysis,” Brain, Behavior, and Immunity, vol. 21, no. 7, pp. 901–912, 2007. View at Publisher · View at Google Scholar · View at Scopus
  14. M. A. Gupta, A. K. Gupta, and H. F. Haberman, “Psoriasis and psychiatry: an update,” General Hospital Psychiatry, vol. 9, no. 3, pp. 157–166, 1987. View at Publisher · View at Google Scholar · View at Scopus
  15. R. Sandyk and R. Pardeshi, “Mood-dependent fluctuations in the severity of tardive dyskinesia and psoriasis vulgaris in a patient with schizoaffective disorder: possible role of melatonin,” International Journal of Neuroscience, vol. 50, no. 3-4, pp. 215–221, 1990. View at Publisher · View at Google Scholar · View at Scopus
  16. L. Arborelius, M. J. Owens, P. M. Plotsky, and C. B. Nemeroff, “The role of corticotropin-releasing factor in depression and anxiety disorders,” Journal of Endocrinology, vol. 160, no. 1, pp. 1–12, 1999. View at Publisher · View at Google Scholar · View at Scopus
  17. M. Joëls and E. R. de Kloet, “Mineralocorticoid and glucocorticoid receptors in the brain. Implications for ion permeability and transmitter systems,” Progress in Neurobiology, vol. 43, no. 1, pp. 1–36, 1994. View at Publisher · View at Google Scholar · View at Scopus
  18. L. Jacobson and R. Sapolsky, “The role of the hippocampus in feedback regulation of the hypothalamic-pituitary-adrenocortical axis,” Endocrine Reviews, vol. 12, no. 2, pp. 118–134, 1991. View at Publisher · View at Google Scholar · View at Scopus
  19. B. Zbytek, A. Mysliwski, A. Slominski, J. Wortsman, E. T. Wei, and J. Mysliwska, “Corticotropin-releasing hormone affects cytokine production in human HaCaT keratinocytes,” Life Sciences, vol. 70, no. 9, pp. 1013–1021, 2002. View at Publisher · View at Google Scholar · View at Scopus
  20. M.-E. Quevedo, A. Slominski, W. Pinto, E. Wel, and J. Wortsman, “Pleiotropic effects of corticotropin releasing hormone on normal human skin keratinocytes,” In Vitro Cellular and Developmental Biology: Animal, vol. 37, no. 1, pp. 50–54, 2001. View at Publisher · View at Google Scholar · View at Scopus
  21. B. Zbytek, L. M. Pfeffer, and A. T. Slominski, “Corticotropin-releasing hormone stimulates NF-κB in human epidermal keratinocytes,” Journal of Endocrinology, vol. 181, no. 3, pp. R1–R7, 2004. View at Google Scholar · View at Scopus
  22. J. E. Kim, D. H. Cho, H. S. Kim et al., “Expression of the corticotropin-releasing hormone-proopiomelanocortin axis in the various clinical types of psoriasis,” Experimental Dermatology, vol. 16, no. 2, pp. 104–109, 2007. View at Publisher · View at Google Scholar · View at Scopus
  23. N. Ito, T. Ito, A. Kromminga et al., “Human hair follicles display a functional equivalent of the hypothalamic-pituitary-adrenal axis and synthesize cortisol,” The FASEB Journal, vol. 19, no. 10, pp. 1332–1334, 2005. View at Publisher · View at Google Scholar · View at Scopus
  24. M. O'Kane, E. P. Murphy, and B. Kirby, “The role of corticotropin-releasing hormone in immune-mediated cutaneous inflammatory disease,” Experimental Dermatology, vol. 15, no. 3, pp. 143–153, 2006. View at Publisher · View at Google Scholar · View at Scopus
  25. T. Tsuchiya and I. Horii, “Epidermal cell proliferative activity assessed by proliferating cell nuclear antigen (PCNA) decreases following immobilization-induced stress in male Syrian hamsters,” Psychoneuroendocrinology, vol. 21, no. 1, pp. 111–117, 1996. View at Publisher · View at Google Scholar · View at Scopus
  26. M. Denda, T. Tsuchiya, P. M. Elias, and K. R. Feingold, “Stress alters cutaneous permeability barrier homeostasis,” The American Journal of Physiology—Regulatory Integrative and Comparative Physiology, vol. 278, no. 2, pp. R367–R372, 2000. View at Google Scholar · View at Scopus
  27. H. L. Richards, D. W. Ray, B. Kirby et al., “Response of the hypothalamic-pituitary-adrenal axis to psychological stress in patients with psoriasis,” British Journal of Dermatology, vol. 153, no. 6, pp. 1114–1120, 2005. View at Publisher · View at Google Scholar · View at Scopus
  28. A. Garg, M.-M. Chren, L. P. Sands et al., “Psychological stress perturbs epidermal permeability barrier homeostasis: implications for the pathogenesis of stress-associated skin disorders,” Archives of Dermatology, vol. 137, no. 1, pp. 53–59, 2001. View at Google Scholar · View at Scopus
  29. R. Ghadially, J. T. Reed, and P. M. Elias, “Stratum corneum structure and function correlates with phenotype in psoriasis,” Journal of Investigative Dermatology, vol. 107, no. 4, pp. 558–564, 1996. View at Publisher · View at Google Scholar · View at Scopus
  30. D. A. Padgett, P. T. Marucha, and J. F. Sheridan, “Restraint stress slows cutaneous wound healing in mice,” Brain, Behavior, and Immunity, vol. 12, no. 1, pp. 64–73, 1998. View at Publisher · View at Google Scholar · View at Scopus
  31. M. Ebrecht, J. Hextall, L.-G. Kirtley, A. Taylor, M. Dyson, and J. Weinman, “Perceived stress and cortisol levels predict speed of wound healing in healthy male adults,” Psychoneuroendocrinology, vol. 29, no. 6, pp. 798–809, 2004. View at Publisher · View at Google Scholar · View at Scopus
  32. J. K. Kiecolt-Glaser, P. T. Marucha, A. M. Mercado, W. B. Malarkey, and R. Glaser, “Slowing of wound healing by psychological stress,” The Lancet, vol. 346, no. 8984, pp. 1194–1196, 1995. View at Publisher · View at Google Scholar · View at Scopus
  33. S. D. Kreibig, “Autonomic nervous system activity in emotion: a review,” Biological Psychology, vol. 84, no. 3, pp. 394–421, 2010. View at Publisher · View at Google Scholar · View at Scopus
  34. A. Z. Scalco, M. U. P. B. Rondon, I. C. Trombetta et al., “Muscle sympathetic nervous activity in depressed patients before and after treatment with sertraline,” Journal of Hypertension, vol. 27, no. 12, pp. 2429–2436, 2009. View at Publisher · View at Google Scholar · View at Scopus
  35. D. A. Barton, T. Dawood, E. A. Lambert et al., “Sympathetic activity in major depressive disorder: identifying those at increased cardiac risk?” Journal of Hypertension, vol. 25, no. 10, pp. 2117–2124, 2007. View at Publisher · View at Google Scholar · View at Scopus
  36. R. C. Veith, N. Lewis, O. A. Linares et al., “Sympathetic nervous system activity in major depression: basal and desipramine-induced alterations in plasma norepinephrine kinetics,” Archives of General Psychiatry, vol. 51, no. 5, pp. 411–422, 1994. View at Publisher · View at Google Scholar · View at Scopus
  37. M. V. Singh, M. W. Chapleau, S. C. Harwani, and F. M. Abboud, “The immune system and hypertension,” Immunologic Research, vol. 59, no. 1–3, pp. 243–253, 2014. View at Publisher · View at Google Scholar
  38. K. M. Grebe, K. Takeda, H. D. Hickman et al., “Cutting edge: sympathetic nervous system increases proinflammatory cytokines and exacerbates influenza A virus pathogenesis,” Journal of Immunology, vol. 184, no. 2, pp. 540–544, 2010. View at Publisher · View at Google Scholar · View at Scopus
  39. Y. Katayama, M. Battista, W.-M. Kao et al., “Signals from the sympathetic nervous system regulate hematopoietic stem cell egress from bone marrow,” Cell, vol. 124, no. 2, pp. 407–421, 2006. View at Publisher · View at Google Scholar · View at Scopus
  40. P. Saint-Mezard, C. Chavagnac, S. Bosset et al., “Psychological stress exerts an adjuvant effect on skin dendritic cell functions in vivo,” The Journal of Immunology, vol. 171, no. 8, pp. 4073–4080, 2003. View at Publisher · View at Google Scholar · View at Scopus
  41. A. Buske-Kirschbaum, M. Ebrecht, S. Kern, and D. H. Hellhammer, “Endocrine stress responses in TH1-mediated chronic inflammatory skin disease (psoriasis vulgaris)—do they parallel stress-induced endocrine changes in TH2-mediated inflammatory dermatoses (atopic dermatitis)?” Psychoneuroendocrinology, vol. 31, no. 4, pp. 439–446, 2006. View at Publisher · View at Google Scholar · View at Scopus
  42. G. Schmid-Ott, R. Jacobs, B. Jäger et al., “Stress-induced endocrine and immunological changes in psoriasis patients and healthy controls. A preliminary study,” Psychotherapy and Psychosomatics, vol. 67, no. 1, pp. 37–42, 1998. View at Publisher · View at Google Scholar · View at Scopus
  43. C. L. Lubahn, D. Lorton, J. A. Schaller, S. J. Sweeney, and D. L. Bellinger, “Targeting α- and β-adrenergic receptors differentially shifts Th1, Th2, and inflammatory cytokine profiles in immune organs to attenuate adjuvant arthritis,” Frontiers in Immunology, vol. 5, article 346, 2014. View at Publisher · View at Google Scholar
  44. K. H. Basavaraj, N. M. Ashok, R. Rashmi, and T. K. Praveen, “The role of drugs in the induction and/or exacerbation of psoriasis,” International Journal of Dermatology, vol. 49, no. 12, pp. 1351–1361, 2010. View at Publisher · View at Google Scholar · View at Scopus
  45. S. Wu, J. Han, W.-Q. Li, and A. A. Qureshi, “Hypertension, antihypertensive medication use, and risk of psoriasis,” JAMA Dermatology, vol. 150, no. 9, pp. 957–963, 2014. View at Publisher · View at Google Scholar · View at Scopus
  46. D. Kovacs, M. Falchi, G. Cardinali et al., “Immunohistochemical analysis of keratinocyte growth factor and fibroblast growth factor 10 expression in psoriasis,” Experimental Dermatology, vol. 14, no. 2, pp. 130–137, 2005. View at Publisher · View at Google Scholar · View at Scopus
  47. N. Yao, J.-X. Xia, X.-M. Liu et al., “Topical application of a new monoclonal antibody against fibroblast growth factor 10 (FGF 10) mitigates propranolol-induced psoriasis-like lesions in guinea pigs,” European Review for Medical and Pharmacological Sciences, vol. 18, no. 7, pp. 1085–1091, 2014. View at Google Scholar · View at Scopus
  48. F. S. Dhabhar, “Effects of stress on immune function: the good, the bad, and the beautiful,” Immunologic Research, vol. 58, no. 2-3, pp. 193–210, 2014. View at Publisher · View at Google Scholar · View at Scopus
  49. F. S. Dhabhar, “Enhancing versus suppressive effects of stress on immune function: implications for immunoprotection and immunopathology,” NeuroImmunoModulation, vol. 16, no. 5, pp. 300–317, 2009. View at Publisher · View at Google Scholar · View at Scopus
  50. J. E. Carroll, C. A. Low, A. A. Prather et al., “Negative affective responses to a speech task predict changes in interleukin (IL)-6,” Brain, Behavior, and Immunity, vol. 25, no. 2, pp. 232–238, 2011. View at Publisher · View at Google Scholar · View at Scopus
  51. E. Puterman, E. S. Epel, A. O’Donovan, A. A. Prather, K. Aschbacher, and F. S. Dhabhar, “Anger is associated with increased IL-6 stress reactivity in women, but only among those low in social support,” International Journal of Behavioral Medicine, vol. 21, no. 6, pp. 936–945, 2013. View at Publisher · View at Google Scholar · View at Scopus
  52. M. J. Maher, P. A. Mora, and H. Leventhal, “Depression as a predictor of perceived social support and demand: a componential approach using a prospective sample of older adults,” Emotion, vol. 6, no. 3, pp. 450–458, 2006. View at Publisher · View at Google Scholar · View at Scopus
  53. E. Stice, P. Rohde, J. Gau, and C. Ochner, “Relation of depression to perceived social support: results from a randomized adolescent depression prevention trial,” Behaviour Research and Therapy, vol. 49, no. 5, pp. 361–366, 2011. View at Publisher · View at Google Scholar · View at Scopus
  54. S. Sephton and D. Spiegel, “Circadian disruption in cancer: a neuroendocrine-immune pathway from stress to disease?” Brain, Behavior, and Immunity, vol. 17, no. 5, pp. 321–328, 2003. View at Publisher · View at Google Scholar · View at Scopus
  55. E. M. J. Peters, C. Liezmann, B. F. Klapp, and J. Kruse, “The neuroimmune connection interferes with tissue regeneration and chronic inflammatory disease in the skin,” Annals of the New York Academy of Sciences, vol. 1262, no. 1, pp. 118–126, 2012. View at Publisher · View at Google Scholar · View at Scopus
  56. C. E. Wright, P. C. Strike, L. Brydon, and A. Steptoe, “Acute inflammation and negative mood: mediation by cytokine activation,” Brain, Behavior, and Immunity, vol. 19, no. 4, pp. 345–350, 2005. View at Publisher · View at Google Scholar · View at Scopus
  57. A. J. Dunn, A. H. Swiergiel, and R. de Beaurepaire, “Cytokines as mediators of depression: what can we learn from animal studies?” Neuroscience and Biobehavioral Reviews, vol. 29, no. 4-5, pp. 891–909, 2005. View at Publisher · View at Google Scholar · View at Scopus
  58. D. Gimeno, M. Kivimäki, E. J. Brunner et al., “Associations of C-reactive protein and interleukin-6 with cognitive symptoms of depression: 12-year follow-up of the Whitehall II study,” Psychological Medicine, vol. 39, no. 3, pp. 413–423, 2009. View at Publisher · View at Google Scholar · View at Scopus
  59. S. Tyring, A. Gottlieb, K. Papp et al., “Etanercept and clinical outcomes, fatigue, and depression in psoriasis: double-blind placebo-controlled randomised phase III trial,” The Lancet, vol. 367, no. 9504, pp. 29–35, 2006. View at Publisher · View at Google Scholar · View at Scopus
  60. L. Capuron, G. Neurauter, D. L. Musselman et al., “Interferon-alpha-induced changes in tryptophan metabolism. Relationship to depression and paroxetine treatment,” Biological Psychiatry, vol. 54, no. 9, pp. 906–914, 2003. View at Publisher · View at Google Scholar · View at Scopus
  61. M. Maes, B. E. Leonard, A. M. Myint, M. Kubera, and R. Verkerk, “The new ‘5-HT’ hypothesis of depression: cell-mediated immune activation induces indoleamine 2,3-dioxygenase, which leads to lower plasma tryptophan and an increased synthesis of detrimental tryptophan catabolites (TRYCATs), both of which contribute to the onset of depression,” Progress in Neuro-Psychopharmacology and Biological Psychiatry, vol. 35, no. 3, pp. 702–721, 2011. View at Publisher · View at Google Scholar · View at Scopus
  62. J. Wang and A. J. Dunn, “Mouse interleukin-6 stimulates the HPA axis and increases brain tryptophan and serotonin metabolism,” Neurochemistry International, vol. 33, no. 2, pp. 143–154, 1998. View at Publisher · View at Google Scholar · View at Scopus
  63. R. P. Brown, J. H. Kocsis, S. Caroff et al., “Depressed mood and reality disturbance correlate with decreased nocturnal melatonin in depressed patients,” Acta Psychiatrica Scandinavica, vol. 76, no. 3, pp. 272–275, 1987. View at Publisher · View at Google Scholar · View at Scopus
  64. L. B. Kartha, L. Chandrashekar, M. Rajappa et al., “Serum melatonin levels in psoriasis and associated depressive symptoms,” Clinical Chemistry and Laboratory Medicine, vol. 52, no. 6, pp. e123–e125, 2014. View at Publisher · View at Google Scholar
  65. A. Carrillo-Vico, P. J. Lardone, N. Álvarez-Śnchez, A. Rodrĩguez-Rodrĩguez, and J. M. Guerrero, “Melatonin: buffering the immune system,” International Journal of Molecular Sciences, vol. 14, no. 4, pp. 8638–8683, 2013. View at Publisher · View at Google Scholar · View at Scopus
  66. E. Esposito and S. Cuzzocrea, “Antiinflammatory activity of melatonin in central nervous system,” Current Neuropharmacology, vol. 8, no. 3, pp. 228–242, 2010. View at Publisher · View at Google Scholar · View at Scopus
  67. A. Miles and D. Philbrick, “Melatonin: perspectives in laboratory medicine and clinical research,” Critical Reviews in Clinical Laboratory Sciences, vol. 25, no. 3, pp. 231–253, 1987. View at Publisher · View at Google Scholar · View at Scopus
  68. N. Mozzanica, G. Tadini, A. Radaelli et al., “Plasma melatonin levels in psoriasis,” Acta Dermato-Venereologica, vol. 68, no. 4, pp. 312–316, 1988. View at Google Scholar · View at Scopus
  69. M. Ozler, K. Simsek, C. Ozkan et al., “Comparison of the effect of topical and systemic melatonin administration on delayed wound healing in rats that underwent pinealectomy,” Scandinavian Journal of Clinical and Laboratory Investigation, vol. 70, no. 6, pp. 447–452, 2010. View at Publisher · View at Google Scholar · View at Scopus
  70. A. J. Thody and S. Shuster, “Control of sebaceous gland function in the rat by α melanocyte stimulating hormone,” Journal of Endocrinology, vol. 64, no. 3, pp. 503–510, 1975. View at Publisher · View at Google Scholar · View at Scopus
  71. K. R. Feingold and P. M. Elias, “Endocrine-skin interactions. Cutaneous manifestations of adrenal disease, pheochromocytomas, carcinoid syndrome, sex hormone excess and deficiency, polyglandular autoimmune syndromes, multiple endocrine neoplasia syndromes, and other miscellaneous disorders,” Journal of the American Academy of Dermatology, vol. 19, no. 1, part 1, pp. 1–20, 1988. View at Publisher · View at Google Scholar · View at Scopus
  72. S. N. Goyal, D. M. Kokare, C. T. Chopde, and N. K. Subhedar, “Alpha-melanocyte stimulating hormone antagonizes antidepressant-like effect of neuropeptide Y in Porsolt's test in rats,” Pharmacology Biochemistry and Behavior, vol. 85, no. 2, pp. 369–377, 2006. View at Publisher · View at Google Scholar · View at Scopus
  73. D. M. Kokare, M. P. Dandekar, P. S. Singru, G. L. Gupta, and N. K. Subhedar, “Involvement of alpha-MSH in the social isolation induced anxiety- and depression-like behaviors in rat,” Neuropharmacology, vol. 58, no. 7, pp. 1009–1018, 2010. View at Publisher · View at Google Scholar · View at Scopus
  74. R. H. Ehrensing and A. J. Kastin, “Melanocyte-stimulating hormone-release inhibiting hormone as a antidepressant. A pilot study,” Archives of General Psychiatry, vol. 30, no. 1, pp. 63–65, 1974. View at Publisher · View at Google Scholar · View at Scopus
  75. M.-S. Lee, R.-Y. Lin, and M.-S. Lai, “Increased risk of diabetes mellitus in relation to the severity of psoriasis, concomitant medication, and comorbidity: a nationwide population-based cohort study,” Journal of the American Academy of Dermatology, vol. 70, no. 4, pp. 691–698, 2014. View at Publisher · View at Google Scholar · View at Scopus
  76. E. Peschke and E. Mühlbauer, “New evidence for a role of melatonin in glucose regulation,” Best Practice & Research Clinical Endocrinology & Metabolism, vol. 24, no. 5, pp. 829–841, 2010. View at Publisher · View at Google Scholar
  77. G. Boden, J. Ruiz, J.-L. Urbain, and X. Chen, “Evidence for a circadian rhythm of insulin secretion,” American Journal of Physiology—Endocrinology and Metabolism, vol. 271, part 1, no. 2, pp. E246–E252, 1996. View at Google Scholar · View at Scopus
  78. V. Lyssenko, C. L. F. Nagorny, M. R. Erdos et al., “Common variant in MTNR1B associated with increased risk of type 2 diabetes and impaired early insulin secretion,” Nature Genetics, vol. 41, no. 1, pp. 82–88, 2009. View at Publisher · View at Google Scholar · View at Scopus
  79. I. Prokopenko, C. Langenberg, J. C. Florez et al., “Variants in MTNR1B influence fasting glucose levels,” Nature Genetics, vol. 41, no. 1, pp. 77–81, 2009. View at Publisher · View at Google Scholar
  80. T. Sparsø, A. Bonnefond, E. Andersson et al., “G-allele of intronic rs10830963 in MTNR1B confers increased risk of impaired fasting glycemia and type 2 diabetes through an impaired glucose-stimulated insulin release: studies involving 19,605 Europeans,” Diabetes, vol. 58, no. 6, pp. 1450–1456, 2009. View at Publisher · View at Google Scholar · View at Scopus
  81. M. M. Zanquetta, P. M. Seraphim, D. H. Sumida, J. Cipolla-Neto, and U. F. Machado, “Calorie restriction reduces pinealectomy-induced insulin resistance by improving GLUT4 gene expression and its translocation to the plasma membrane,” Journal of Pineal Research, vol. 35, no. 3, pp. 141–148, 2003. View at Publisher · View at Google Scholar · View at Scopus
  82. D. M. Kemp, M. Ubeda, and J. F. Habener, “Identification and functional characterization of melatonin Mel 1a receptors in pancreatic β cells: potential role in incretin-mediated cell function by sensitization of cAMP signaling,” Molecular and Cellular Endocrinology, vol. 191, no. 2, pp. 157–166, 2002. View at Publisher · View at Google Scholar · View at Scopus
  83. P. L. Montilla, J. F. Vargas, I. F. Túnez et al., “Oxidative stress in diabetic rats induced by streptozotocin: protective effects of melatonin,” Journal of Pineal Research, vol. 25, no. 2, pp. 94–100, 1998. View at Publisher · View at Google Scholar · View at Scopus
  84. H. Vural, T. Sabuncu, S. Oktay Arslan, and N. Aksoy, “Melatonin inhibits lipid peroxidation and stimulates the antioxidant status of diabetic rats,” Journal of Pineal Research, vol. 31, no. 3, pp. 193–198, 2001. View at Publisher · View at Google Scholar · View at Scopus
  85. M. Kanter, H. Uysal, T. Karaca, and H. O. Sagmanligil, “Depression of glucose levels and partial restoration of pancreatic beta-cell damage by melatonin in streptozotocin-induced diabetic rats,” Archives of Toxicology, vol. 80, no. 6, pp. 362–369, 2006. View at Publisher · View at Google Scholar · View at Scopus
  86. R. J. Reiter, D.-X. Tan, S. J. Kim et al., “Augmentation of indices of oxidative damage in life-long melatonin—deficient rats,” Mechanisms of Ageing and Development, vol. 110, no. 3, pp. 157–173, 1999. View at Publisher · View at Google Scholar · View at Scopus
  87. R. J. Reiter, D.-X. Tan, and S. Burkhardt, “Reactive oxygen and nitrogen species and cellular and organismal decline: amelioration with melatonin,” Mechanisms of Ageing and Development, vol. 123, no. 8, pp. 1007–1019, 2002. View at Publisher · View at Google Scholar · View at Scopus
  88. M. Tiedge, S. Lortz, J. Drinkgern, and S. Lenzen, “Relation between antioxidant enzyme gene expression and antioxidative defense status of insulin-producing cells,” Diabetes, vol. 46, no. 11, pp. 1733–1742, 1997. View at Publisher · View at Google Scholar · View at Scopus
  89. D. Giugliano, A. Ceriello, and G. Paolisso, “Oxidative stress and diabetic vascular complications,” Diabetes Care, vol. 19, no. 3, pp. 257–267, 1996. View at Publisher · View at Google Scholar · View at Scopus
  90. C. J. Mullarkey, D. Edelstein, and M. Brownlee, “Free radical generation by early glycation products: a mechanism for accelerated atherogenesis in diabetes,” Biochemical and Biophysical Research Communications, vol. 173, no. 3, pp. 932–939, 1990. View at Publisher · View at Google Scholar · View at Scopus
  91. S. P. Wolff, “Diabetes mellitus and free radicals. Free radicals, transition metals and oxidative stress in the aetiology of diabetes mellitus and complications,” British Medical Bulletin, vol. 49, no. 3, pp. 642–652, 1993. View at Google Scholar · View at Scopus
  92. S. Nishida, T. Segawa, I. Murai, and S. Nakagawa, “Long-term melatonin administration reduces hyperinsulinemia and improves the altered fatty-acid compositions in type 2 diabetic rats via the restoration of Delta-5 desaturase activity,” Journal of Pineal Research, vol. 32, no. 1, pp. 26–33, 2002. View at Publisher · View at Google Scholar · View at Scopus
  93. R. G. B. Langley, G. G. Krueger, and C. E. M. Griffiths, “Psoriasis: epidemiology, clinical features, and quality of life,” Annals of the Rheumatic Diseases, vol. 64, no. 2, pp. ii18–ii25, 2005. View at Publisher · View at Google Scholar · View at Scopus
  94. S. M. Hill, C. Cheng, L. Yuan et al., “Age-related decline in melatonin and Its MT1 receptor are associated with decreased sensitivity to melatonin and enhanced mammary tumor growth,” Current Aging Science, vol. 6, no. 1, pp. 125–133, 2013. View at Publisher · View at Google Scholar · View at Scopus
  95. A. Cavallo, S. R. Daniels, L. M. Dolan, J. A. Bean, and J. C. Khoury, “Blood pressure-lowering effect of melatonin in type 1 diabetes,” Journal of Pineal Research, vol. 36, no. 4, pp. 262–266, 2004. View at Publisher · View at Google Scholar · View at Scopus
  96. F. A. J. L. Scheer, G. A. Van Montfrans, E. J. W. Van Someren, G. Mairuhu, and R. M. Buijs, “Daily nighttime melatonin reduces blood pressure in male patients with essential hypertension,” Hypertension, vol. 43, no. 2, pp. 192–197, 2004. View at Publisher · View at Google Scholar · View at Scopus
  97. E. Grossman, M. Laudon, R. Yalcin et al., “Melatonin reduces night blood pressure in patients with nocturnal hypertension,” The American Journal of Medicine, vol. 119, no. 10, pp. 898–902, 2006. View at Publisher · View at Google Scholar · View at Scopus
  98. M.-W. Hung, G. M. Kravtsov, C.-F. Lau, A. M.-S. Poon, G. L. Tipoe, and M.-L. Fung, “Melatonin ameliorates endothelial dysfunction, vascular inflammation, and systemic hypertension in rats with chronic intermittent hypoxia,” Journal of Pineal Research, vol. 55, no. 3, pp. 247–256, 2013. View at Publisher · View at Google Scholar · View at Scopus
  99. A. Ö. Sehirli, D. Koyun, Ş. Tetik et al., “Melatonin protects against ischemic heart failure in rats,” Journal of Pineal Research, vol. 55, no. 2, pp. 138–148, 2013. View at Publisher · View at Google Scholar
  100. R. Johnson, L. Staiano-Coico, L. Austin, I. Cardinale, R. Nabeya-Tsukifuji, and J. G. Krueger, “PUVA treatment selectively induces a cell cycle block and subsequent apoptosis in human T-lymphocytes,” Photochemistry and Photobiology, vol. 63, no. 5, pp. 566–571, 1996. View at Publisher · View at Google Scholar · View at Scopus
  101. T. J. Laing, B. C. Richardson, M. B. Toth, E. M. Smith, and R. M. Marks, “Ultraviolet light and 8-methoxypsoralen inhibit expression of endothelial adhesion molecules,” The Journal of Rheumatology, vol. 22, no. 11, pp. 2126–2131, 1995. View at Google Scholar · View at Scopus
  102. G. Sethi and A. Sodhi, “Role of p38 mitogen-activated protein kinase and caspases in UV-B-induced apoptosis of murine peritoneal macrophages,” Photochemistry and Photobiology, vol. 79, no. 1, pp. 48–54, 2004. View at Publisher · View at Google Scholar · View at Scopus
  103. T. P. Singh, M. P. Schön, K. Wallbrecht et al., “8-Methoxypsoralen plus ultraviolet a therapy acts via inhibition of the IL-23/Th17 axis and induction of Foxp3+ regulatory T cells involving CTLA4 signaling in a psoriasis-like skin disorder,” Journal of Immunology, vol. 184, no. 12, pp. 7257–7267, 2010. View at Publisher · View at Google Scholar · View at Scopus
  104. A. Mizara, L. Papadopoulos, and S. R. McBride, “Core beliefs and psychological distress in patients with psoriasis and atopic eczema attending secondary care: the role of schemas in chronic skin disease,” British Journal of Dermatology, vol. 166, no. 5, pp. 986–993, 2012. View at Publisher · View at Google Scholar · View at Scopus
  105. D. G. Fortune, H. L. Richards, B. Kirby, S. Bowcock, C. J. Main, and C. E. M. Griffiths, “A cognitive-behavioural symptom management programme as an adjunct in psoriasis therapy,” British Journal of Dermatology, vol. 146, no. 3, pp. 458–465, 2002. View at Publisher · View at Google Scholar · View at Scopus
  106. C. Hemlock, J. S. Rosenthal, and A. Winston, “Fluoxetine-induced psoriasis,” Annals of Pharmacotherapy, vol. 26, no. 2, pp. 211–212, 1992. View at Google Scholar · View at Scopus
  107. L. T. P. Lin and S. K. Kwek, “Onset of psoriasis during therapy with fluoxetine,” General Hospital Psychiatry, vol. 32, no. 4, pp. 446.e9–446.e10, 2010. View at Publisher · View at Google Scholar · View at Scopus
  108. D. Deandrea, N. Walker, M. Mehlmauer, and K. White, “Dermatological reactions to lithium: a critical review of the literature,” Journal of Clinical Psychopharmacology, vol. 2, no. 3, pp. 199–204, 1982. View at Google Scholar · View at Scopus
  109. V. J. Selmanowitz, “Lithium, leukocytes, and lesions,” Clinics in Dermatology, vol. 4, no. 1, pp. 170–175, 1986. View at Publisher · View at Google Scholar · View at Scopus
  110. H.-S. Moon, A. Mizara, and S. R. McBride, “Psoriasis and psycho-dermatology,” Dermatology and Therapy, vol. 3, no. 2, pp. 117–130, 2013. View at Publisher · View at Google Scholar · View at Scopus